Table 1. Patients included in the blind study.
| Dxa | code | Age (years) | sex | TST (mm) | Tuberculin stimulated (10 µg per ml) | ESAT-6 stimulated (20 µg of peptide per ml) | ||
| CD4 T-cells (%)b | IFN-γ (IU)c | CD4 T-cells (%)b | FN-γ(IU)c | |||||
| Patients with smear and/or culture positive pulmonary TB | ||||||||
| 1 | B1 | 45.94 | m | 6 | 0.1430 | 4.90 | 0.0158 | 0.15 |
| 1 | B3 | 81.57 | f | 10 | 0.2962 | 1.33 | 0.0000 | nd |
| 1 | B11 | 32.96 | m | nd | 0.1833 | 3.77 | 0.0066 | 0.00 |
| 1 | B12 | 50.63 | f | 10 | 0.1298 | 4.00 | 0.0029 | 0.00 |
| 1 | B33 | 31.85 | f | nd | 0.0143 | 0.69 | 0.0010 | 0.00 |
| 1 | B48 | 66.23 | m | nd | 0.0740 | 1.42 | 0.0005 | 0.00 |
| 1 | B49 | 14.99 | m | <5 | 0.1031 | 10.59 | 0.0007 | 0.00 |
| 1 | B52 | 71.11 | m | <5 | 0.1374 | 1.10 | 0.0143 | 0.21 |
| 1 | B61 | 28.51 | m | nd | 0.1411 | 9.03 | 0.0494 | 1.46 |
| 1 | B75 | 75.85 | f | 35 | 0.3035 | 10.23 | Nd | 1.00 |
| 1 | B76 | 95.69 | m | nd | 1.2005 | 4.08 | 0.0121 | 0.01 |
| 1 | B77 | 28.64 | f | 5 | 0.8713 | 44.79 | 0.0439 | 1.83 |
| Patients with smear and culture negative pulmonary TB | ||||||||
| 3 | B21 | 35.33 | f | 20 | 0.1405 | 1.99 | 0.0023 | 0.00 |
| 2 | B29 | 69.58 | m | <5 | 0.0012 | 0.00 | 0.0013 | 0.00 |
| 2 | B40 | 50.41 | m | 10 | 0.3424 | 12.89 | 0.0003 | 0.00 |
| 2 | B42 | 41.97 | m | 28 | 0.1359 | 5.86 | 0.0005 | 0.00 |
| 4 | B46 | 71.33 | m | 30 | 0.5766 | 13.37 | 0.0360 | 0.69 |
| 2 | B47 | 66.7 | m | <5 | 0.0200 | 0.04 | 0.0043 | 0.00 |
| 2 | B59 | 64.73 | m | 5 | 0.0926 | 0.43 | 0.0012 | 0.00 |
| 2 | B65 | 74.38 | m | nd | 0.0034 | 0.00 | 0.0049 | 0.00 |
| 2 | B70 | 70.99 | f | <5 | 0.0026 | 0.03 | 0.0016 | 0.00 |
| 2 | B73 | 15.82 | m | 10 | 0.0145 | 0.00 | 0.0046 | 0.00 |
| Patients with pulmonary TB at least one year after beginning of treatment | ||||||||
| 2 | B7 | 21.22 | m | 12 | 0.1996 | 6.59 | 0.0209 | 0.41 |
| 1 | B22 | 50.24 | f | nd | 0.3246 | 16.66 | 0.0023 | 0.12 |
| 1 | B27 | 58.56 | m | 16 | 0.2539 | 7.79 | 0.0018 | 0.00 |
| 1 | B43 | 76.38 | f | 12 | 0.7997 | 3.23 | 0.0049 | 0.01 |
| 1 | B51 | 36.46 | m | nd | 0.0221 | nd | 0.0222 | nd |
| 1 | B56 | 61.23 | f | <5 | 0.0417 | 0.24 | 0.0178 | 0.15 |
| 1 | B57 | 60.11 | m | <5 | 0.0788 | 2.18 | 0.0006 | 0.00 |
| 1 | B58 | 37.47 | f | 25 | 0.0308 | 2.41 | 0.0252 | 0.26 |
| 1 | B60 | 49.69 | m | 5 | 0.0764 | 2.59 | 0.0009 | 0.00 |
| Control patients | ||||||||
| 6 | B8 | 44.68 | f | <5 | 0.0151 | 0.00 | 0.0039 | 0.00 |
| 6 | B10 | 58.92 | m | <5 | 0.0471 | 0.00 | 0.0161 | 0.00 |
| 6 | B15 | 71.3 | m | <5 | 0.0252 | 0.01 | 0.0001 | nd |
| 6 | B16 | 55.11 | f | nd | 0.0022 | 0.02 | nd | 0.00 |
| 6 | B17 | 40.84 | m | <5 | 0.1161 | 1.00 | 0.0030 | 0.00 |
| 6 | B18 | 65.85 | f | nd | 0.0613 | 0.25 | 0.0121 | nd |
| 6 | B23 | 70.01 | m | <5 | 0.2552 | 2.55 | 0.0060 | 0.00 |
| 6 | B24 | 42.35 | m | <5 | 0.0273 | 0.02 | 0.0046 | 0.00 |
| 6 | B25 | 76.07 | f | <5 | 0.0255 | 0.00 | 0.0012 | 0.00 |
| 6 | B26 | 69.91 | f | nd | 0.0086 | 0.00 | 0.0000 | 7.12 |
| 6 | B28 | 64.3 | m | <5 | 0.0078 | 0.23 | 0.0007 | 0.00 |
| 6 | B35 | 48.05 | m | <5 | 0.0058 | 0.27 | 0.0013 | 0.00 |
| 6 | B36 | 58.67 | m | nd | 0.0088 | 0.16 | 0.0063 | 0.00 |
| 6 | B39 | 47.24 | m | <5 | 0.3653 | 6.06 | 0.0040 | 0.72 |
| 6 | B41 | 43.94 | m | <5 | 0.0019 | 0.18 | 0.0005 | 0.00 |
| 6 | B44 | 73.7 | m | nd | 0.1972 | 0.50 | 0.0243 | 0.13 |
| 6 | B55 | 54.19 | m | <5 | 0.0035 | 0.01 | 0.0017 | 0.00 |
a
mainstay of diagnosis: 1 = positive culture and/or microscopy, 2 = mycobacteria in biopsy, 3 = therapy response, 4 = typical chest film, TST >15 mm, positive response to ESAT-6
b
results exceeding 1 positive event per 10,000 cells were counted as positive and are shown in bold
c
some of these results exceed the threshold for positivity published for a commercial assay (Quantiferon Gold, Cellestis) of 0.35 IU.